Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Given Average Rating of "Hold" by Analysts

Key Points

• Analysts rate Kestra Medical Technologies as a "Hold" on average (5 firms), with a 12‑month consensus price target of $27.40 and individual targets ranging roughly from $17 (Goldman) to $32 (BTIG).
• The stock trades near $19.25 with a $1.12B market cap; the company reported a ($0.61) EPS miss and revenue up 62.7% year‑over‑year but remains unprofitable with deeply negative margins and ROE.
• Insiders have been selling (15,000 shares by Brian Webster on Mar 17; 45,000 total in the last 90 days) even as some institutions (Eventide, Brown Advisory, Summit Partners) materially increased their positions.

Shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report) have been assigned an average rating of "Hold" from the five ratings firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $27.40.

A number of equities research analysts have weighed in on the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Kestra Medical Technologies in a report on Monday, March 23rd. BTIG Research restated a "buy" rating and set a $32.00 price objective on shares of Kestra Medical Technologies in a report on Tuesday. Wells Fargo & Company boosted their price objective on Kestra Medical Technologies from $27.00 to $28.00 and gave the company an "overweight" rating in a report on Friday, December 12th. Stifel Nicolaus set a $30.00 price objective on Kestra Medical Technologies in a report on Friday, December 12th. Finally, The Goldman Sachs Group decreased their price objective on Kestra Medical Technologies from $22.00 to $17.00 and set a "neutral" rating for the company in a report on Thursday.

Kestra Medical Technologies Trading Down 1.9%

Shares of KMTS stock opened at $19.25 on Friday. The company has a market cap of $1.12 billion and a P/E ratio of -4.86. The stock has a 50 day simple moving average of $22.79 and a two-hundred day simple moving average of $24.48. The company has a debt-to-equity ratio of 0.15, a quick ratio of 7.32 and a current ratio of 7.32. Kestra Medical Technologies has a fifty-two week low of $13.25 and a fifty-two week high of $30.00.

Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last issued its earnings results on Tuesday, March 17th. The company reported ($0.61) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.01). The business had revenue of $24.55 million during the quarter. Kestra Medical Technologies had a negative return on equity of 65.49% and a negative net margin of 171.87%.The firm's quarterly revenue was up 62.7% compared to the same quarter last year.

Insider Activity at Kestra Medical Technologies

In other news, insider Brian Daniel Webster sold 15,000 shares of the business's stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $20.27, for a total transaction of $304,050.00. Following the completion of the sale, the insider owned 364,786 shares in the company, valued at $7,394,212.22. The trade was a 3.95% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders sold a total of 45,000 shares of company stock worth $1,030,050 in the last ninety days. Insiders own 3.60% of the company's stock.

Institutional Investors Weigh In On Kestra Medical Technologies

Hedge funds and other institutional investors have recently modified their holdings of the company. Eventide Asset Management LLC increased its holdings in shares of Kestra Medical Technologies by 285.7% during the second quarter. Eventide Asset Management LLC now owns 1,060,557 shares of the company's stock valued at $17,584,000 after acquiring an additional 785,557 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Kestra Medical Technologies during the third quarter valued at approximately $562,000. Russell Investments Group Ltd. boosted its position in shares of Kestra Medical Technologies by 43.5% during the fourth quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company's stock valued at $41,000 after buying an additional 474 shares during the last quarter. Summit Partners Public Asset Management LLC purchased a new position in shares of Kestra Medical Technologies during the fourth quarter valued at approximately $9,282,000. Finally, Brown Advisory Inc. boosted its position in shares of Kestra Medical Technologies by 34.1% during the fourth quarter. Brown Advisory Inc. now owns 1,688,356 shares of the company's stock valued at $44,775,000 after buying an additional 428,996 shares during the last quarter.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.